Hemogenyx Pharmaceuticals Plc
(“Hemogenyx” or the “Company”)
Hemogenyx to Present at the ‘From Laboratory to Clinic’ Translational Research Conference in Oxford
Hemogenyx Pharmaceuticals Plc (LSE: HEMO), the Standard Listed biopharmaceutical group developing new therapies and treatments designed to transform bone marrow transplantation for the treatment of blood diseases, announces that its CEO, Dr. Vladislav Sandler, will present at the Kennedy Institute of Rheumatology conference ‘From Laboratory to Clinic: Accelerating Experimental Medicine Approaches’ taking place at Trinity College, Oxford, from Tuesday 4 September until Friday 7 September 2018.
Dr. Sandler’s presentation is entitled “Mouse-Human Hematopoietic Chimeras for Disease Modelling and Drug Development” and describes Hemogenyx’s new platform technology that it uses as an engine for novel product development. These novel humanized mice, with a chimeric mouse-human blood system, are the subject of a provisional patent application filing by the Company, as announced in February 2018, and are being used as a tool for drug development and testing, including in a collaboration with a major US biotechnology company, and in a collaboration with The Rockefeller University focused on auto-immune disease modelling to develop new treatments for such diseases.
The Kennedy Institute of Rheumatology is part of the University of Oxford’s Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Science, which comprises more than 25 research groups working in the areas of immunity and microbiome, inflammation biology and tissue re-modelling/regeneration.
Enquiries:
| Hemogenyx Pharmaceuticals Limited | www.hemogenyx.com | |
| Dr Vladislav Sandler, Chief Executive Officer & Co-Founder | Via Walbrook PR | |
| Sir Marc Feldmann, Executive Chairman | ||
| Optiva Securities Ltd | Tel: +44 (0)20 3137 1902 | |
| Christian Dennis | ||
| Shard Capital Partners LLP | Tel: +44 (0)20 7186 9950 | |
| Damon Heath, Erik Woolgar | ||
| Peterhouse Corporate Finance Limited | Tel: +44 (0)20 7469 0930 | |
| Lucy Williams, Duncan Vasey | ||
| Walbrook PR (UK Media & Investor Relations) | Tel: +44 (0)20 7933 8780 or hemogenyx@walbrookpr.com | |
| Paul McManus | Mob: +44 (0)7980 541 893 | |
| US Media enquiries | ||
| Lowell Goodman | Tel: +1 (323) 646-3249 or Lowell@corbomitecomms.com | |
About Hemogenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals PLC. is a publicly traded company (LSE: HEMO) headquartered in London, with its wholly owned US operating subsidiary, Hemogenyx LLC, located in Brooklyn, New York at its state- of- the- art research facility (“Hemogenyx”).
For more than 50 years, bone marrow transplantation has been used to save the lives of patients suffering from blood diseases. The risk of toxicity and death that are associated with bone marrow transplantation, however, have meant that the procedure is used only as a last resort and its use is restricted. Hemogenyx’s technology has the potential to enable many more patients suffering from devastating blood diseases, such as leukemia and lymphoma, as well as severe autoimmune diseases, such as multiple sclerosis, aplastic anemia and systemic lupus erythematosus (Lupus), to benefit from bone marrow transplantation.
Hemogenyx is a pre-clinical stage biopharmaceutical group developing new medicines and treatments to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Hemogenyx is developing two distinct and complementary products, as well as a platform technology that it uses as an engine for novel product development.
END
MSCUAONRWAAWOAR